reactive arthritis: Reactive arthritis (ReA) is an autoimmune disorder belonging to the group of seronegative spondyloarthropathies and is characterized by the classic triad of arthritis, urethritis and conjunctivitis.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
385 |
4. Check minimum number of eventsNone |
385 |
5. Include endpointsNone |
385 |
6. Filter based on genotype QC (FinnGen only) |
358 |
Control definitions (FinnGen only)
- Control exclude
- RHEUMA_ARHTROPAT_REACTIVE
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M02
- Name in latin
- Arthropathia post infectionem intestinalem
Similar endpoints
↥List of similar endpoints to
Postdysenteric arthropathy
based on the number of shared cases.
Similar with more cases:
- Reactive arthropathies, FINNGEN
- Reactive arthropathies
- Finngen Rheumatological endpoints
- Arthropathies
- Diseases of the musculoskeletal system and connective tissue
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2221 | 1079 | 1138 |
| Only index persons | 2145 | 1048 | 1097 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.03 |
| Only index persons | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 45.19 | 45.69 | 44.72 |
| Only index persons | 44.97 | 45.57 | 44.40 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 358 | 193 | 165 |
| Unadjusted period prevalence (%) | 0.07 | 0.07 | 0.08 |
| Median age at first event (years) | 47.04 | 46.28 | 47.91 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 365
- Matched controls
- 3650
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M02.1
ICD-10 Finland
Postdysenteric arthropathy
+∞
307.7
364
*
A07EC01
ATC
sulfasalazine; oral, rectal
21.9
186.3
172
143
M02.9
ICD-10 Finland
Reactive arthropathy, unspecified
860.7
127.6
118
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
12.4
123.1
161
218
M13.9
ICD-10 Finland
Arthritis, unspecified
13.4
111.2
126
138
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
12.9
96.7
109
117
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
12.2
92.3
108
122
L04AX03
ATC
methotrexate; systemic
7.8
66.2
114
202
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
13.3
50.9
51
44
H02AB06
ATC
prednisolone; systemic
5.5
50.6
266
1201
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
13.3
49.1
49
42
L88
ICPC
Rheumatoid/seropositive arthritis
11.3
48.4
54
55
M02.8
ICD-10 Finland
Other reactive arthropathies
255.7
45.0
45
*
L01BA01
ATC
methotrexate; systemic
11.8
40.1
43
41
M45
ICD-10 Finland
Ankylosing spondylitis
11.1
36.0
40
40
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
7.7
32.7
49
72
J01MA02
ATC
ciprofloxacin; systemic
3.4
28.7
193
915
P01BA02
ATC
hydroxychloroquine; oral
5.1
28.0
66
151
L04AB04
ATC
adalimumab; parenteral
10.4
25.3
29
30
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.2
21.8
113
447
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
20.5
17.1
25
13
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
7.4
16.7
25
36
M25.5
ICD-10 Finland
Pain in joint
2.4
15.3
163
907
A02BC02
ATC
pantoprazole; systemic
2.7
15.0
275
1945
H02AB07
ATC
prednisone; oral
3.1
14.8
69
252
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
6.6
13.9
23
37
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.4
13.7
132
695
L04AB01
ATC
etanercept; parenteral
15.8
13.3
21
14
S01BA01
ATC
dexamethasone; ophthalmic
5.5
13.2
26
50
NA6BG
NOMESCO Finland
Sacro-iliac joint MRI examination with high intensity magnet
11.1
12.4
23
22
M00.9
ICD-10 Finland
Pyogenic arthritis, unspecified
16.6
12.3
19
12
L04AB06
ATC
golimumab; parenteral
22.2
12.1
17
8
A02.0
ICD-10 Finland
Salmonella enteritis
26.0
11.2
15
6
M01AH01
ATC
celecoxib; oral
2.6
11.0
75
333
N02AX02
ATC
tramadol; systemic, rectal
2.0
10.0
175
1137
M13.1
ICD-10 Finland
Monoarthritis, not elsewhere classified
12.7
10.0
17
14
M01AH05
ATC
etoricoxib; oral
2.1
9.9
253
1882
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
2.8
9.8
54
214
M02.3
ICD-10 Finland
Reiter disease
+∞
9.4
9
*
M46.1
ICD-10 Finland
Sacroiliitis, not elsewhere classified
11.1
9.4
17
16
K52.9
ICD-10 Finland
Noninfective gastroenteritis and colitis, unspecified
4.2
9.2
25
63
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.0
9.2
157
1003
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
3.7
9.0
29
83
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
6.9
8.8
21
32
A04.5
ICD-10 Finland
Campylobacter enteritis
11.1
8.4
15
14
M02
ICD-10 Finland
Reactive arthropathies
+∞
8.4
8
*
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
7.8
8.3
18
24
TNG10
NOMESCO Finland
Puncture of knee
9.2
8.1
16
18
M01AE02
ATC
naproxen; oral, rectal
1.9
8.0
227
1692
ZXX01
NOMESCO Finland
Extent of proceudre, 1 unit
13.4
7.9
13
10
A02BC05
ATC
esomeprazole; systemic
1.9
7.8
157
1047
TNG11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in knee
18.8
7.6
11
6
L04AA01
ATC
[U] ciclosporin
18.8
7.6
11
6
S01BA04
ATC
prednisolone; ophthalmic
6.7
7.5
18
28
M03.2*A04.6
ICD-10 Finland
Postinfectious arthropathy in enteritis due to Yersinia enterocolitica
+∞
7.3
7
*
4AB02, ,
NOMESCO Finland
30.7
7.2
9
*
L04AA13
ATC
[U] leflunomide
5.8
7.2
19
34
M03BX02
ATC
tizanidine; oral
1.8
7.1
239
1848
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
2.9
6.8
33
122
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
6.4
172
1230
M01AC06
ATC
meloxicam; systemic, rectal
1.8
6.4
137
918
H20.1
ICD-10 Finland
Chronic iridocyclitis
11.3
6.3
11
10
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.9
6.3
105
651
K30
ICD-10 Finland
Functional dyspepsia
2.2
6.1
52
252
NH3EA
NOMESCO Finland
Feet X-ray examination with load
6.2
6.1
15
25
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
79
76
12.99
74.51
1.7
1.3
—
—
—
0
0
64
73
10.42
53.03
1.8
1.4
17475.77
17182.10
e6/l
0.01
48
52
37
25
16.36
42.24
1.8
1.4
64.26
68.21
%
0.19
27
19
32
17
20.49
21.69
1.7
1.5
28.21
30.00
%
0.07
26
12
133
608
2.87
19.52
1.4
1.3
3.44
9.82
u/ml
1.48
56
250
279
1864
3.11
19.48
11.8
10.1
3.85
4.05
e9/l
1.00
259
1633
320
2398
3.71
16.72
8.8
4.1
12.26
10.64
mm/h
1.20
309
2252
133
653
2.63
16.52
1.4
1.3
22.18
28.71
iu/ml
0.42
53
207
36
77
5.08
16.25
1.9
1.5
—
—
—
0
0
152
834
2.41
14.52
2.9
2.7
319.63
340.40
umol/l
1.98
140
751
58
205
3.17
13.04
1.3
1.3
59.26
30.54
au/ml
—
5
15
61
228
3.01
12.44
2.4
2.4
41.49
17.20
au/ml
—
10
20
240
1705
2.19
11.24
5.0
3.6
0.00
0.00
estimate
0.50
63
346
241
1725
2.17
10.93
5.1
3.6
0.00
0.00
estimate
-0.00
63
346
241
1744
2.12
10.37
5.2
3.6
0.00
0.94
estimate
0.50
55
320
21
26
8.50
9.97
1.4
1.1
7733.00
496409.75
e6/l
0.82
16
20
296
2418
2.19
7.98
11.1
8.4
77.75
79.62
u/l
0.37
290
2303
30
96
3.32
7.88
1.3
1.4
—
—
—
0
0
199
1439
1.84
7.52
2.8
2.5
77.20
75.44
nmol/l
0.38
190
1313
31
108
3.04
7.09
1.8
1.6
0.27
0.05
iu/ml
—
7
17
143
974
1.77
6.28
4.4
3.1
0.00
0.11
estimate
0.63
57
279
45
204
2.38
6.19
1.6
1.6
—
—
—
0
0
180
1322
1.71
5.96
5.0
3.4
0.00
0.01
estimate
0.69
59
294
135
918
1.75
5.88
5.8
3.6
0.00
0.01
estimate
0.69
59
321
81
477
1.90
5.64
1.7
2.3
—
—
—
0
0
77
447
1.92
5.59
1.7
2.2
—
—
—
0
0
25
89
2.94
5.53
1.3
1.1
—
—
—
0
0
24
89
2.82
4.95
1.3
1.1
—
—
—
0
0
146
1066
1.62
4.62
2.9
3.4
2.34
2.36
mmol/l
0.57
133
968
81
510
1.76
4.47
2.5
2.5
14.11
13.52
umol/l
0.31
76
476
36
174
2.19
4.28
1.8
1.3
—
—
—
0
0
14
41
3.51
4.22
1.2
1.5
—
—
—
0
0
14
41
3.51
4.22
1.2
1.5
—
—
—
0
0
14
41
3.51
4.22
1.2
1.5
—
—
—
0
0
334
3042
2.15
4.18
19.1
13.8
87.85
85.84
ml/min/173m2
1.04
318
2794
99
676
1.64
4.02
1.5
1.6
—
—
—
0
0
195
1557
1.54
4.02
3.5
3.0
115.35
122.21
ug/l
0.22
187
1467
110
777
1.60
3.87
2.3
2.0
2.68
2.82
mg/l
0.36
98
660
342
3163
2.29
3.79
23.9
14.5
26.32
22.90
mg/l
0.93
318
2555
117
843
1.57
3.77
1.5
1.3
0.82
1.86
u/ml
1.04
37
249
121
886
1.55
3.61
3.5
2.9
0.24
0.40
e6/l
0.84
96
633
86
587
1.61
3.45
3.2
2.7
2.43
2.45
mmol/l
0.81
75
530
10
22
4.64
3.45
1.2
1.1
268.90
166.03
iu/ml
—
10
22
354
3341
2.98
3.44
18.0
11.8
26.26
27.61
u/l
1.00
349
3271
13
37
3.60
3.44
1.2
1.5
—
—
—
0
0
170
1353
1.48
3.35
14.0
11.5
1.18
1.19
inr
0.09
139
1115
13
38
3.51
3.34
1.2
1.5
—
—
—
0
0
13
38
3.51
3.34
1.2
1.5
—
—
—
0
0
12
34
3.61
3.22
1.2
1.2
—
—
—
0
0
277
2456
1.53
3.02
4.6
4.3
14.74
14.64
pmol/l
0.25
266
2277
166
1335
1.45
3.01
4.9
5.3
36.32
36.37
g/l
0.04
154
1271
320
2937
1.73
2.99
5.5
5.3
1.78
1.87
mu/l
0.95
305
2748
22
103
2.21
2.87
2.1
1.5
—
—
—
0
0
15
59
2.61
2.82
1.1
1.3
—
304.00
—
0
5
30
160
1.95
2.80
2.2
2.2
16.93
4.98
iu/ml
—
7
38
113
854
1.47
2.80
1.8
1.6
19.87
20.20
nmol/l
0.10
105
727
18
79
2.34
2.72
1.9
2.7
0.60
2.48
index
—
5
44
76
533
1.54
2.69
2.8
2.7
0.59
0.71
e6/l
0.25
42
259
17
74
2.36
2.62
1.1
1.2
—
—
—
0
0
99
739
1.47
2.59
1.7
1.6
0.70
1.20
mg/l
3.47
77
570
76
550
1.48
2.31
3.0
3.4
0.82
0.82
mmol/l
0.02
70
528
212
1839
1.36
2.23
4.2
5.5
6.42
6.63
mmol/l
0.94
206
1741
7
19
3.73
2.16
1.4
1.6
—
—
—
0
0
6
14
4.34
2.16
1.3
1.7
—
—
—
0
0
6
14
4.34
2.16
1.3
1.8
—
—
—
0
0
195
1679
1.35
2.10
5.9
7.1
10.11
11.31
umol/l
1.95
188
1601
10
38
2.68
2.02
1.4
1.6
—
—
—
0
0
22
119
1.90
2.02
1.2
1.3
—
—
—
0
0
141
1164
1.34
1.98
4.1
3.4
84.20
35.52
ng/l
0.34
80
766
246
2207
1.35
1.95
3.7
3.3
—
—
—
0
0
68
499
1.45
1.92
2.9
2.8
1.79
2.10
e6/l
0.14
32
225
55
390
1.48
1.85
2.3
3.0
4.57
7.98
umol/l
2.39
50
335
6
18
3.37
1.75
1.3
1.7
—
—
—
0
0
9
36
2.54
1.75
1.4
1.6
—
—
—
0
0
5
13
3.88
1.72
1.8
1.2
11.20
13.31
u/l
—
5
13
28
173
1.67
1.69
1.1
1.0
—
—
—
0
0
12
55
2.22
1.69
1.3
2.0
—
—
—
0
0
116
953
1.32
1.64
2.6
2.1
130.00
203.83
u/l
2.41
108
915
5
14
3.61
1.62
1.0
1.2
—
—
—
0
0
5
14
3.61
1.62
1.0
1.0
—
—
—
0
0
45
316
1.48
1.60
2.4
2.6
68.42
35.18
u/l
0.51
38
265
5
15
3.36
1.53
1.0
1.1
—
—
—
0
0
15
81
1.89
1.42
1.1
1.1
0.23
2.15
u/ml
—
7
43
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
17
2.97
1.36
1.0
1.1
—
—
—
0
0
72
571
1.33
1.29
1.7
1.7
467.57
38934868.08
pmol/l
0.77
67
488
5
18
2.80
1.29
1.0
1.0
—
—
—
0
0
8
35
2.31
1.27
2.0
1.3
15.37
2.90
ug/l
—
8
30
170
1506
1.24
1.25
6.4
7.7
1.22
1.21
mmol/l
0.56
148
1323
92
763
1.28
1.19
5.4
3.7
1.02
1.02
kg/l
0.67
66
502
5
20
2.52
1.15
1.0
1.0
3090.84
1532.50
miu/ml
—
5
20
8
40
2.02
1.12
1.3
1.3
—
—
—
0
0
312
2978
1.33
1.12
6.1
6.2
37.97
38.97
mmol/mol
1.51
300
2835
12
66
1.85
1.10
1.2
1.8
—
—
—
0
0
153
1355
1.22
1.09
5.9
7.1
1.21
1.21
mmol/l
0.04
148
1267
15
89
1.71
1.09
1.5
1.4
209.22
298.69
ug/g
—
9
51
119
1028
1.23
1.08
3.3
2.9
69.93
66.77
u/l
0.08
112
958
152
1351
1.21
1.04
2.3
2.0
99.47
97.36
pmol/l
0.22
90
710
11
60
1.86
1.04
1.4
1.7
—
—
—
0
0
75
618
1.27
1.02
3.2
2.8
0.66
0.74
ug/l
0.52
42
368
19
124
1.56
0.99
1.7
1.6
10.14
8.85
u/ml
—
5
28
31
225
1.41
0.98
1.9
2.1
—
—
—
0
0
12
69
1.76
0.97
1.3
1.6
—
—
—
0
0
9
50
1.82
0.97
1.3
1.9
—
—
—
0
0
14
85
1.67
0.95
3.4
2.8
1.50
1.56
ratio
—
6
44
32
236
1.39
0.93
1.6
2.9
79.06
69.48
ml/min/173m2
1.03
16
102
16
102
1.59
0.92
1.3
1.3
—
—
—
0
0
47
370
1.31
0.91
1.8
1.9
—
—
—
0
0
60
490
1.27
0.89
2.1
2.0
—
—
—
0
0
8
44
1.84
0.86
1.1
1.2
—
—
—
0
0
35
267
1.34
0.85
2.0
2.2
—
—
—
0
0
45
357
1.30
0.84
1.8
2.0
—
—
—
0
0
54
440
1.27
0.82
1.7
1.6
1358.25
1181.09
nmol/l
0.65
46
346
89
767
1.21
0.82
2.9
2.3
—
—
—
0
0
11
66
1.69
0.79
1.2
1.4
—
—
—
0
0
8
48
1.68
0.79
1.3
1.4
—
—
—
0
0
8
48
1.68
0.79
1.3
1.4
—
—
—
0
0
6
34
1.78
0.76
1.0
1.1
—
—
—
0
0
9
54
1.68
0.75
1.0
1.1
—
—
—
0
0
11
171
0.63
0.74
1.7
2.7
0.45
0.64
%
1.33
11
171
7
38
1.86
0.74
1.0
1.2
—
72.20
—
0
5
10
60
1.69
0.73
5.4
2.6
6.60
7.54
pmol/l
—
10
60
16
109
1.49
0.72
3.1
2.0
0.42
3.62
ug/l
0.69
16
99
114
1018
1.17
0.71
3.5
4.3
20.39
10.53
mg/mmol
0.59
76
647
5
26
1.94
0.71
1.4
1.5
59.80
71.58
umol/l
—
5
26
7
117
0.59
0.69
1.1
1.9
274.71
231.89
pmol/l
—
7
109
27
349
0.76
0.68
5.0
10.7
0.31
0.71
mmol/l
0.30
19
300
5
29
1.73
0.64
1.0
1.2
—
—
—
0
0
10
152
0.65
0.62
1.2
1.1
0.89
0.90
g/l
—
10
152
9
139
0.64
0.61
1.2
1.5
266.89
306.12
mu/l
—
9
129
6
35
1.73
0.58
1.0
1.1
—
—
—
0
0
6
35
1.73
0.58
1.0
1.4
149.55
179.39
pmol/l
—
6
35
244
2330
1.14
0.56
3.7
3.6
48.20
48.46
u/l
0.02
233
2223
158
1469
1.13
0.55
2.6
2.9
—
—
estimate
—
0
0
10
147
0.67
0.54
1.2
1.1
1.47
1.54
g/l
—
10
147
11
74
1.50
0.54
1.4
1.7
—
—
—
0
0
17
126
1.37
0.52
1.5
2.1
1.45
1.51
g/l
0.10
17
113
14
100
1.42
0.52
3.2
1.7
—
—
—
0
0
29
234
1.26
0.51
1.3
1.3
92.00
120.50
u/ml
0.33
11
94
13
92
1.43
0.51
1.4
1.9
—
—
—
0
0
90
811
1.15
0.50
4.0
4.1
21.30
22.26
%
0.30
42
348
111
1017
1.13
0.48
5.0
4.8
1.59
1.96
ug/l
0.88
102
923
34
283
1.22
0.47
3.6
4.5
70.23
22.40
ug/l
0.31
24
234
16
120
1.35
0.47
3.1
1.5
1.31
1.17
g/l
0.90
16
115
12
86
1.41
0.45
1.5
1.8
—
—
—
0
0
35
294
1.21
0.45
5.0
2.9
—
—
—
0
0
7
51
1.38
0.44
1.3
1.6
—
—
—
0
0
11
150
0.73
0.42
1.6
1.4
—
—
—
0
0
14
183
0.76
0.41
1.4
1.6
0.26
0.32
mg/l
—
7
84
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
8
59
1.36
0.41
4.8
4.4
—
3440.25
—
0
8
0
17
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
0.97
—
0
10
119
1108
1.11
0.39
2.9
3.5
8.16
8.15
mmol/l
0.00
108
960
11
80
1.39
0.39
1.5
1.5
—
—
—
0
0
125
1169
1.11
0.38
2.8
3.4
33.69
32.72
u/l
0.09
120
1108
65
585
1.14
0.38
3.8
3.7
74.59
386.41
ng/l
2.15
45
418
16
125
1.29
0.37
1.1
1.5
—
—
—
0
0
282
2747
1.12
0.36
24.2
18.8
332.52
333.19
g/l
0.59
282
2740
9
71
1.27
0.36
1.7
1.6
—
—
—
0
0
88
813
1.11
0.34
3.5
3.2
1635.01
1039.75
ng/l
0.38
75
668
13
103
1.27
0.28
3.5
2.0
—
—
—
0
0
8
62
1.30
0.28
1.6
1.5
60.20
49.78
ug/l
—
8
62
8
65
1.24
0.27
1.6
1.9
—
—
—
0
0
6
82
0.73
0.24
2.3
1.3
—
—
—
0
0
15
124
1.22
0.24
1.0
1.4
286.43
280.80
miu/ml
—
6
64
27
238
1.15
0.23
1.3
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
8
104
0.76
0.21
1.5
1.9
221.75
190.56
%
—
8
104
15
126
1.20
0.21
1.3
2.3
1716.02
8372.29
u/l
—
5
43
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
6
48
1.25
0.20
1.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
2.4
—
—
—
0
0
0
14
0.00
0.20
0.0
2.4
—
—
—
0
0
0
14
0.00
0.20
0.0
2.4
—
—
—
0
0
34
370
0.91
0.16
4.3
4.7
31.29
31.55
%
0.05
21
252
19
169
1.13
0.15
1.9
1.6
—
—
—
0
0
9
83
1.09
0.14
1.1
1.3
—
—
—
0
0
300
3026
0.95
0.10
4.4
4.3
1.32
1.31
mmol/l
0.13
287
2821
11
96
1.15
0.10
1.0
1.2
—
—
—
0
0
44
418
1.06
0.10
1.7
2.1
3.47
3.61
ratio
0.34
32
325
34
320
1.07
0.10
7.2
6.9
—
—
—
0
0
34
321
1.07
0.09
1.5
1.9
3.83
3.52
mmol/l
0.76
22
229
319
3169
1.05
0.09
5.2
5.1
4.76
4.68
mmol/l
0.80
307
2997
12
134
0.89
0.09
1.4
1.6
—
—
—
0
0
29
306
0.94
0.07
2.6
3.9
1.73
1.71
mmol/l
0.01
23
262
8
78
1.03
0.07
2.0
1.5
—
164.55
—
0
22
14
152
0.92
0.06
1.2
1.9
51.64
38.43
nmol/l
1.21
14
146
53
544
0.97
0.04
1.4
1.5
—
—
—
0
0
321
3198
1.03
0.04
5.8
5.7
2.80
2.76
mmol/l
0.34
308
3018
305
3038
1.02
0.03
5.1
4.9
5.82
5.90
mmol/l
0.68
295
2837
317
3159
1.03
0.03
5.1
5.0
1.47
1.45
mmol/l
0.42
306
2971
141
1398
1.01
0.02
2.1
2.0
1.34
1.39
mmol/l
0.30
124
1203
43
424
1.02
0.00
5.9
7.6
105.16
104.17
mmol/l
0.95
43
424
10
97
1.03
0.00
1.6
1.4
—
—
—
0
0
10
95
1.05
0.00
1.5
2.9
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
10.4
—
10.06
—
0
5
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
8.1
—
5.87
—
0
7
5
59
0.85
-0.00
1.0
1.3
19.32
14.01
u/l
—
5
50
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.6
—
68.24
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
5
55
0.91
-0.00
1.6
3.1
16.00
32.05
u/ml
—
5
55
Mortality – FinRegistry
↥Association
Association between endpoint ARTRHO_POSTDYSENTERIC and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ARTRHO_POSTDYSENTERIC | 1.182 [0.9, 1.55] | 0.228 |
| Birth year | 0.999 [0.99, 1.01] | 0.765 |
During the follow-up period (1.1.1998 — 31.12.2019), 79 out of 974 females with ARTRHO_POSTDYSENTERIC died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ARTRHO_POSTDYSENTERIC | 0.814 [0.65, 1.02] | 0.071 |
| Birth year | 0.986 [0.98, 1.0] | 0.007 |
During the follow-up period (1.1.1998 — 31.12.2019), 80 out of 1010 males with ARTRHO_POSTDYSENTERIC died.
Mortality risk
Mortality risk for people of age
years, who have ARTRHO_POSTDYSENTERIC.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.104% | 0.138% |
| 5 | 0.787% | 0.85% |
| 10 | 1.998% | 2.199% |
| 15 | 3.78% | 4.239% |
| 20 | 6.482% | 7.309% |
Relationships between endpoints
↥Index endpoint: ARTRHO_POSTDYSENTERIC – Postdysenteric arthropathy
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data